Exhibit 99.1

 

 

Synthorx Reports First Quarter Financial Results

 

SAN DIEGO, CA – April 30, 2019 – Synthorx, Inc. (Nasdaq: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today reported financial results and provided a business update for the first quarter ended March 31, 2019.

 

“Our accomplishments so far this year reflect our commitment to leveraging our proprietary Expanded Genetic Alphabet platform to design novel cytokine Synthorins and advance our programs in cancer and autoimmune disorders,” said Laura Shawver, president and chief executive officer. “We are building a robust dossier of preclinical safety and efficacy data for our lead program, THOR-707, providing enthusiasm leading to an Investigational New Drug application for THOR-707 in the second quarter. We are eager to start clinical trials soon thereafter.”

 

First Quarter 2019 and Other Recent Highlights

 

Presented Preclinical Data at the CSCO Conference on Immunotherapy. In March 2019, Synthorx presented data at the Chinese Society for Clinical Oncology (CSCO) Conference on Immunotherapy demonstrating that THOR-707, an engineered not-alpha interleukin-2 (IL-2) for the treatment of solid tumors, induces strong immunological responses in vivo.

 

Presented Preclinical Data at AACR. In April 2019, Synthorx presented data at the American Association of Cancer Research (AACR) Annual Meeting 2019 showing that THOR-707 elicits durable pharmacodynamic responses and efficacy alone and in combination with an anti-PD-1 therapy in multiple mouse models.

 

To Present Preclinical Data at ASCO. Synthorx will present data showing the use of synthetic biology to reprogram the therapeutic activity of IL-2 at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held May 31st through June 4th, 2019 in Chicago, IL.

 

Financial Results

For the first quarter ended March 31, 2019, Synthorx reported a net loss of $10.9 million, compared to a net loss of $2.2 million for the comparable period in 2018.

 

Research and development expenses for the first quarter ended March 31, 2019 were $9.6 million, compared to $1.8 million for the same period in 2018. The increase in the company’s research and development expenses in 2019 was primarily attributable to the advancement of its THOR-707 program and related activities, including additional costs incurred in the first quarter of 2019 as the company prepares to file its IND application in the second quarter of 2019, combined with additional personnel and related costs as Synthorx has expanded its research and development team to support the development efforts for its programs.

 


The following information was filed by Synthorx, Inc. (THOR) on Tuesday, April 30, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Synthorx, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Synthorx, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Log in with your credentials

or    

Forgot your details?

Create Account